Literature DB >> 15015926

Harm reduction approaches to reducing tobacco-related mortality.

Dorothy K Hatsukami1, Jack E Henningfield, Michael Kotlyar.   

Abstract

Tobacco harm reduction approaches are gaining increased attention. Much of this attention is due to a growing concern that significant populations of smokers either do not want to quit or believe they are unable to quit smoking, and to a concern over tobacco-industry attempts to produce tobacco products that claim to result in less toxin exposure. Decreasing tobacco toxin exposure as a method for reducing mortality and morbidity may be a reasonable tobacco control strategy. However, the impact of this strategy must be explored both on individual and population levels. A significant amount of independent research is needed to inform policy decisions. Regulatory authority over potential reduced exposure products is also essential.

Entities:  

Mesh:

Year:  2004        PMID: 15015926     DOI: 10.1146/annurev.publhealth.25.102802.124406

Source DB:  PubMed          Journal:  Annu Rev Public Health        ISSN: 0163-7525            Impact factor:   21.981


  27 in total

1.  A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.

Authors:  Andrea R Vansickel; Caroline O Cobb; Michael F Weaver; Thomas E Eissenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 2.  Medication screening for smoking cessation: a proposal for new methodologies.

Authors:  Kenneth A Perkins; Maxine Stitzer; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

3.  A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats.

Authors:  Andrew C Harris; Paul R Pentel; Danielle Burroughs; Mylissa D Staley; Mark G Lesage
Journal:  Psychopharmacology (Berl)       Date:  2011-04-15       Impact factor: 4.530

4.  Characteristics of physically active smokers and implications for harm reduction.

Authors:  Wayne K Deruiter; Guy Faulkner; John Cairney; Scott Veldhuizen
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

Review 5.  Measures for assessing subjective effects of potential reduced-exposure products.

Authors:  Karen Hanson; Richard O'Connor; Dorothy Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

6.  Predictors of smoking reduction among Blacks.

Authors:  Carla J Berg; Janet L Thomas; Hongfei Guo; Lawrence C An; Kolawole S Okuyemi; Tracie C Collins; Jasjit S Ahluwalia
Journal:  Nicotine Tob Res       Date:  2010-03-01       Impact factor: 4.244

Review 7.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 8.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

9.  The Minnesota SimSmoke Tobacco Control Policy Model of Smokeless Tobacco and Cigarette Use.

Authors:  David T Levy; Zhe Yuan; Yameng Li; Ann W St Claire; Barbara A Schillo
Journal:  Am J Prev Med       Date:  2019-10       Impact factor: 5.043

10.  Smokers' use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC Four Country Survey.

Authors:  David Hammond; Jessica L Reid; Pete Driezen; K Michael Cummings; Ron Borland; Geoffrey T Fong; Ann McNeill
Journal:  Addiction       Date:  2008-10       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.